Clinical trial · Interventional
Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung Cancer
Feasibility of Assisted-VATS(Video-Assisted Thoracoscopic Surgery) Sleeve Lobectomy for Non-small Cell Lung Cancer
NCT00997724CI-TRIAL-00002957VATSunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine the feasibility of assisted-VATS (video-assisted thoracoscopic surgery) sleeve lobectomy for non-small cell lung cancer for non-small cell lung cancer. Success is defined as assisted-VATS sleeve lobectomy without conversion. If success rate over 90%, assisted-VATS sleeve lobectomy is considered as feasible procedures for non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| a-VATS | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- a-VATS
- description
- Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
- interventionNames
- Procedure: a-VATS
Primary outcomes (1)
- measure
- If success rate over 90%, assisted-VATS sleeve lobectomy is considered as feasible procedures for non-small cell lung cancer. (Success is defined as assisted-VATS sleeve lobectomy without conversion).
- timeFrame
- 3 months
Secondary outcomes (1)
- measure
- To evaluate the intraoperative(surgical duration, estimated blood loss), postoperative variables(mortality, morbidity, chest tube drainage duration, hospital stay), and 5-year survival rates.
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed non-small cell lung cancer (Squamous, adenosquamous, large cell, or poorly differentiated) * Patients with central tumors located at the origin of a lobar bronchus. * ECOG performance status 0-1 * Hematopoietic: WBC at least 4,000/mm\^3; Platelet count at least 100,000/mm\^3 * Hepatic: Bilirubin normal; AST/ALT no greater than 1.5 times upper limit of normal (ULN); Alkaline phosphatase no greater than 2.5 times ULN * Renal: Creatinine clearance greater than 60 ml/min * Cardiovascular: Cardiac function normal Exclusion Criteria: * Severe complications or infections * Pregnant or breast-feeding women * Clinically significant heart disease * Uncontrolled hepatitis, chronic liver disease, or diabetes mellitus * Another active cancer except properly treated carcinoma in situ of the cervix or basal/squamous cell skin carcinoma
References
Publications (1)
- DERIVEDHe J, Shao W, Cao C, Yan TD, Wang D, Xiong X, Yin W, Xu X, Huang J. Long-term outcome of hybrid surgical approach of video-assisted minithoracotomy sleeve lobectomy for non-small-cell lung cancer. Surg Endosc. 2011 Aug;25(8):2509-15. doi: 10.1007/s00464-011-1576-6. Epub 2011 Feb 7. PMID 21298520